Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(55.6%)

Phase 1

3(33.3%)

Phase 2

1(11.1%)

9Total

N/A(5)

Phase 1(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01769716Not ApplicableCompleted

Umbilical Cord Blood Therapy for Global Developmental Delay

Role: lead

NCT01885663Phase 1Completed

UCB Therapy in Acquired Brain Injury

Role: lead

NCT02025972Not ApplicableCompleted

Allogeneic Umbilical Cord Blood Therapy in Children With CP

Role: lead

NCT02236065Not ApplicableCompleted

Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders

Role: lead

NCT01884155Phase 1Completed

Allogeneic Umbilical Cord Blood Therapy for Stroke

Role: lead

NCT01586052Phase 1Completed

Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1

Role: lead

NCT01601158Not ApplicableCompleted

Umbilical Cord Blood Therapy for Children With Global Developmental Delay

Role: lead

NCT01639404Not ApplicableCompleted

Umbilical Cord Blood Therapy for Children With Cerebral Palsy

Role: lead

NCT01528436Phase 2Completed

Umbilical Cord Blood Therapy for Cerebral Palsy

Role: lead

All 9 trials loaded